Tilrekimig clinical trials
Also written PF-07275315.
How each study uses tilrekimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tilrekimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test tilrekimig.
- Nov 2026A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPhase 2 · Pfizer
- Feb 2027A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20Phase 1 · Pfizer
- Mar 2027A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaPhase 2 · Pfizer
Studies
Open first, then newest update. How each study uses tilrekimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaRecruitingPhase 3PfizerNCT07765888Written as Tilrekimig
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaRecruitingPhase 2PfizerNCT06977581Written as PF-07275315
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingPhase 3PfizerNCT07783425Written as Tilrekimig
- A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe AsthmaRecruitingPhase 3PfizerNCT07869043Written as tilrekimig
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaRecruitingPhase 3PfizerNCT07772921Written as tilrekimig
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseRecruitingPhase 2/3PfizerNCT07363694Written as PF-07275315 dose 1
- A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of TimeNot yet recruitingPhase 3PfizerNCT07839884Written as Tilrekimig
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisActive, not recruitingPhase 2PfizerNCT05995964Written as PF-07275315
- A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20Active, not recruitingPhase 1PfizerNCT07792941Written as tilrekimig and rHuPH20
- A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult ParticipantsCompletedPhase 1PfizerNCT06675188Written as PF-07275315
- A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy PeopleCompletedPhase 1PfizerNCT05411588Written as PF-07275315
Codes
What other systems call tilrekimig · ClinicalTrials.gg INT017166
- UNII (FDA) LD48NPB5QSTILREKIMIGOne source FDA
- NCI Thesaurus C211783TilrekimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LD48NPB5QS | TILREKIMIG | One source FDA |
| NCI Thesaurus | C211783 | Tilrekimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.